FierceBiotech 2026-01-20 GSK pays $2.2B to buy Rapt for its phase 2-stage food allergy challenger to Xolair
FierceBiotech 2026-01-20 ARPA-H director eyes future beyond vaccines, ‘winning the biotech race’ against China
Agilent 2026-01-20 Agilent Technologies (A) Initiated with "Buy" Rating by HSBC | A Stock News - GuruFocus
Illumina 2026-01-20 Illumina Inc. (ILMN) Shares See Target Boost as Analysts See Potential 2026 Upside - Insider Monkey
BioPharma Dive 2026-01-20 When every day counts: Building CRO partnerships on a foundation of trust, care and precision
Agilent 2026-01-20 HSBC initiates coverage on Agilent stock with Buy rating, $180 target - Investing.com
Endpoints News 2026-01-20 Exciva raises $59M Series B to fund Phase 2 test of Alzheimer’s agitation drug
Illumina 2026-01-20 The Bull Case For Illumina (ILMN) Could Change Following Its Billion Cell Atlas Pharma Alliance - Yahoo Finance Singapore
Agilent 2026-01-20 Nucleotide Market Is Going to Boom | Agilent Technologies • Bio-Rad Laboratories • QIAGEN - openPR.com
Waters 2026-01-20 Is Waters Corporation the Quiet Wall Street Cheat Code Everyone’s Sleeping On? - AD HOC NEWS
Waters 2026-01-20 Is Waters Corporation the Quiet Wall Street Cheat Code Everyone’s Sleeping On? - AD HOC NEWS
Agilent 2026-01-19 Profit Recap: Is Agilent Technologies Inc showing insider buying - Quarterly Earnings Summary & AI Driven Stock Price Forecasts - baoquankhu1.vn
FierceBiotech 2026-01-19 FDA Grants RMAT Designation to iRegene’s NouvNeu001, Cementing its Lead as the World’s First iPSC Therapy with Both FTD and RMAT Recognitions
FierceBiotech 2026-01-19 AstraZeneca pens $630M pact to secure remaining rights to armored CAR-T from AbelZeta